Janus Henderson Investors

Activity from announced rounds

Activity in this selectionAI

Janus Henderson Investors is an asset manager with specialist healthcare investing capabilities, including a biotechnology strategy that invests in both public and private companies.

Its Biotechnology Innovation strategy uses long-term, research-intensive analysis across the biotech landscape. The healthcare team evaluates businesses addressing unmet medical needs and technologies intended to improve the efficiency and cost of care.

The biotechnology strategy combines long investments with short selling in its portfolio construction. Private-company investment is part of this specialist asset-management activity, alongside the firm’s broader range of investment strategies.

Sources
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$570M
2 disclosed · full round size, not this investor’s share

By stage

Series B1
Series C+1

By primary sector

Biotech1
Space tech1

By country

United States2

Rounds

2 in this selection
Ambrosia Biosciences

Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.

$100MSeries B
Participant
CesiumAstro

CesiumAstro develops communications technology for space and defense applications.

$470MSeries C
Role not disclosed